The world’s largest generic medicines manufacturer, Teva Pharmaceutical Industries Ltd., is at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONE® (glatiramer acetate injection), and product candidate for relapsing and progressive MS, laquinimod – a once-daily oral, investigational, central nervous system (CNS)-active immunomodulator with a novel mechanism of action, which is being developed for the treatment of relapsing-remitting MS (RRMS), progressive MS and Huntington’s disease.
“New COPAXONE® data at this year’s Congress underscore the safety and efficacy of the three-times-a-week treatment, as well as explore the decreased incidence of adverse events for COPAXONE® 40 mg/mL patients, while laquinimod data focus on long-term measures such as disability progression,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva in a press release. “The data being presented emphasizes our dedication to better understanding the long-term benefit of COPAXONE® and potential for laquinimod.”
Teva’s conference booth, “Hope in the Code” will highlight its commitment to personalized medicine. The company will also be hosting a Satellite Symposium, titled “Discovering a New World in MS,” on Thursday, October 8, 2015 beginning 19:15 until 20:15 CEST.
According to the press release, the presentations sponsored by Teva include:
COPAXONE® (glatiramer acetate injection)
- [P314] Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration (GALA) open-label extension study (Poster Session 1, October 8, 2015, 15:45 – 17:00) O. Khan, P. Rieckmann, S. Kolodny, MD. Davis, N. Ashtamker, JR. Steinerman, R. Zivadinov
- [P656] Disease-modifying therapy improved depression symptoms in multiple sclerosis patients: the POSIDONIA study (Poster Session 1, October 8, 2015, 15:45 – 17:00) E. Montanari, M. Conti, D. Maimone, V. Torri Clerici, K. Plewnia, M. Frigo, A. Francia, A. Pala, A. Veneziano
- [EP1319] Comparison of physicochemical, biological and genomic characteristics of differently manufactured glatiramoids to ensure MS patient safety (e-Poster Session 1, October 8, 2015, 15:45 – 17:00) A. Komlosh, T. Hasson, K. Wells-Knecht, T. Molotsky, R. Krispin, G. Papir, D. Pinkert, H. Cooperman, S. Bakshi, S. Kolitz, F. Towfic, B. Weiner, B. Zeskind, D. Laifenfeld, D. Ladkani, V. Weinstein, I. Grossman, M.R. Hayden
- [P1150] Statistical comparison of adverse events for glatiramer acetate 20mg vs 40mg for the treatment of relapsing-remitting multiple sclerosis (Poster Session 2, October 9, 2015, 15:30 – 17:00) F.J. Zagmutt, Y. Wu, A. Grinspan, S. Kolodny, S. Gandhi
- [P1173] Evaluating the effect of enhanced physical activity and energy management on fatigue in patients suffering from multiple sclerosis: the MS TeleCoach study (Poster Session 2, October 9, 2015, 15:45 – 17:00) M. D’hooghe, G. Van Gassen, D. Kos, B. Van Wijmeersch, B. Willekens, D. Decoo, M. Cambron, I.-K. Penner, P. Vanderdonckt, J. Debruyne, R. Crols, A. Lysandropoulos, S. Elsankari, P. Seeldrayers, A. Mélin, P. Laloux, O. Bouquiaux, R. Reznik, G. Nagels
- [P1507] The Glatiramer acetate pregnancy database (Poster Session 2, October 9, 2015, 15:30 – 1700) O. Neudorfer, M. Sandberg-Wollheim, P.K. Coyle, B. Weinstock-Guttman, A. Perrin Ross, A. Grinspan
- [P1517] Glatiramer acetate slows disability progression – results from a 6-year analysis of the UK Risk Sharing Scheme (Poster Session 2, October 9, 2015, 15:30 – 17:00) G. Giovannoni, P. Brex, M. Sumra, E. Walters, K. Schmierer
- [P319] Long-term follow-up of laquinimod in patients with relapsing-remitting multiple sclerosis (Poster Session 1, October 8, 2015, 15:45 – 17:00) G. Comi, T.L. Vollmer, F.D. Lublin, Y. Dadon, T. Gorfine, M.D. Davis, P.S. Sørensen, V. Knappertz
- [P542] Effects of laquinimod on microglia and monocytes following traumatic brain injury (Poster Session 1, October 8, 2015, 15:45 – 17:00) A. Katsumoto, A.S. Miranda, O. Butovsky, Z. Fanek, R.M. Ransohoff, B.T. Lamb
- [P651] Effect of laquinimod, a novel immunomodulator in development for treatment of multiple sclerosis, on cardiac repolarization in healthy subjects: a thorough QT/QTc study (Poster Session 1, October 8, 2015, 15:45 – 17:00) A. Elgart, D. Mimrod, L. Rabinovich-Guilatt, E. Eyal, J. Morganroth, O. Spiegelstein
- [P919] Disability outcome and sample size considerations for PPMS clinical trial efficiency (Poster Session 2, October 9, 2015, 15:30 – 17:00) M.D. Davis, J.R. Steinerman, N. Sasson, V. Knappertz
- [P1089] Laquinimod reduces CNS pathology and demyelination induced by B lymphocytes from multiple sclerosis patients in a novel brain slice model of MS (Poster Session 2, October 9, 2015, 15:30 – 17:00) D.E. Harlow, S. Selva, K.E. Saul, L.J. Jackson, W.B. Macklin, T.L. Vollmer
- [P1090] Laquinimod is protective to oligodendrocytes during lysolecithin-induced demyelination in a murine brain slice model (Poster Session 2, October 9, 2015, 15:30 – 17:00) D.E. Harlow, K.E. Saul, W.B. Macklin, T.L. Vollmer
- [FC153] MRI measures and disability progression in PPMS: analysis of the PROMiSe clinical trial dataset(Free Communications 1, October 9, 2015, 9:39 – 9:51) M.W. Koch, J.R. Steinerman, V. Knappertz, M.D. Davis, G. Giovannoni, G.R. Cutter, J.S. Wolinsky
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?